Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a pioneering biotechnology company based in the United States, focuses on developing innovative cell therapies for the treatment of degenerative diseases. Founded in 2015, Lineage has made significant strides in the regenerative medicine sector, particularly in the fields of ophthalmology and neurology. The company’s core offerings include advanced cell-based therapies, notably its proprietary retinal pigment epithelium (RPE) cells aimed at treating conditions like age-related macular degeneration. Lineage's unique approach leverages its expertise in pluripotent stem cell technology, positioning it as a leader in the regenerative medicine landscape. With a commitment to transforming patient care, Lineage Cell Therapeutics continues to achieve notable milestones, solidifying its reputation in the competitive biopharmaceutical industry.
DitchCarbon Score
How does Lineage Cell Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lineage Cell Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lineage Cell Therapeutics, Inc.'s reported carbon emissions
Lineage Cell Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there are no emissions data or climate commitments available, it is unclear how Lineage Cell Therapeutics is addressing its carbon footprint or contributing to broader climate goals. The lack of reported emissions and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lineage Cell Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
